EOLS · Evolus, Inc.

$6.22 +0.04 (+0.65%) At close · Jul 28

Market Cap

$409.62M

65.85M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
David Moatazedi	CEO	$775,000	—	$3,886,569	$1,296,697	$429,000	$24,948	$6,412,214
Tatjana Mitchell	CFO	$154,224	$100,000	$1,420,509	$1,368,036	$111,200	$9,303	$3,163,272
Sandra Beaver	CFO	$231,904	—	$968,607	$484,746	—	$14,641	$1,699,898
Rui Avelar	Chief Medical Officer and Head of R&D	$545,400	—	$645,756	$323,161	$166,600	$18,167	$1,699,084
Tomoko Yamagishi-Dressler	Former Chief Marketing Officer	$285,163	—	$484,317	$242,378	$73,425	$502,825	$1,588,108

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
David Moatazedi	CEO	$743,750	—	$3,549,882	$1,777,038	$900,000	$28,207	$6,998,877
Rui Avelar	Chief Medical Officer and Head of R&D	$515,725	—	$1,609,966	$463,571	$280,500	$14,851	$2,884,613
Sandra Beaver	CFO	$477,625	—	$694,544	$463,571	$260,800	$14,783	$1,911,323
Tomoko Yamagishi-Dressler	Former Chief Marketing Officer	$429,525	—	$486,182	$324,501	$233,100	$14,749	$1,488,057
Tatjana Mitchell	CFO	—	—	—	—	—	—	—

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
David Moatazedi	CEO	$687,500	—	$7,417,415	$2,075,862	$1,017,800	$41,870	$11,240,447
Rui Avelar	Chief Medical Officer and Head of R&D	$487,750	—	$1,414,034	$691,957	$320,610	$14,827	$2,929,178
Sandra Beaver	CFO	$437,500	—	$1,027,634	$691,957	$287,890	$14,756	$2,459,737
Tomoko Yamagishi-Dressler	Former Chief Marketing Officer	$151,302	$35,000	$595,565	$595,563	$271,530	$43,161	$1,692,121
Tatjana Mitchell	CFO	—	—	—	—	—	—	—

Fiscal 2022

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
David Moatazedi	CEO	$596,875	—	$1,170,002	$1,161,522	$643,200	$27,991	$3,599,590
Sandra Beaver	CFO	$136,818	$100,000	$330,174	$1,125,002	$135,100	$313	$1,827,407
Lauren Silvernail	CFO	$184,167	—	$582,300	$290,381	—	$375,650	$1,432,498
Rui Avelar	Chief Medical Officer and Head of R&D	$469,000	—	$292,498	$290,381	$202,400	$10,633	$1,264,912
Tomoko Yamagishi-Dressler	Former Chief Marketing Officer	—	—	—	—	—	—	—

Fiscal 2021

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
David Moatazedi	CEO	$571,875	—	$2,300,335	—	$632,500	$25,168	$3,529,878
Rui Avelar	Chief Medical Officer and Head of R&D	$445,000	—	$582,300	—	$207,390	$7,687	$1,242,377
Lauren Silvernail	CFO	$439,875	—	$582,300	—	$176,800	$13,212	$1,212,187
Sandra Beaver	CFO	—	—	—	—	—	—	—

Fiscal 2020

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
David Moatazedi	CEO	$527,083	—	$1,232,293	$815,869	$720,500	$7,744	$3,303,489
Michael Jafar	Former Chief Commercial Officer	$342,292	—	$573,360	$411,994	$226,475	$2,588	$1,556,709
Lauren Silvernail	CFO	$407,292	—	$423,340	$258,714	$222,700	$3,820	$1,315,866
Rui Avelar	Chief Medical Officer and Head of R&D	$403,333	—	$423,340	$258,714	$222,576	$5,943	$1,313,906

Fiscal 2019

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
David Moatazedi	CEO	$550,000	—	—	$1,169,813	$555,500	$3,500	$2,278,813
Rui Avelar	Chief Medical Officer and Head of R&D	$400,000	—	—	$561,510	$861,600	$13,500	$1,836,610
Lauren Silvernail	CFO	$425,000	—	—	$421,133	$171,700	$3,500	$1,021,333
Michael Jafar	Former Chief Commercial Officer	$345,000	—	—	$421,133	$139,380	—	$905,513

Fiscal 2018

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
David Moatazedi	CEO	$361,731	$75,000	—	$4,995,803	$361,644	—	$5,794,178
Lauren Silvernail	CFO	$253,365	—	$673,200	$2,604,260	$101,068	$25,000	$3,656,893
Rui Avelar	Chief Medical Officer and Head of R&D	$367,885	—	$1,202,688	$1,425,752	$160,000	—	$3,156,325

Executive changes

Person	Role	Change	Effective	Filed
Vikram Malik	Class II director	Appointed	2026-03-13	2026-03-13
Vikram Malik	Class III director	Resigned	2026-03-13	2026-03-13

Key facts CIK 1570562 CUSIP 30052C107 13F (30d) 23 filings 23 filers Visit website Investor relations